文献速递泌尿男性生殖肿瘤

肾细胞癌的免疫生物学

The Immunobiology of Kidney Cancer.
PubMed 文献 · J Clin Oncol · 2018-10-29

本文综述肾细胞癌(RCC)肿瘤微环境(TME)的独特免疫学特征:基线CD8 T细胞浸润与更差预后相关,尽管肿瘤突变负荷较低但对PD-1/PD-L1阻断有应答。近期临床数据支持免疫检查点联合治疗及抗血管生成联合PD-1/PD-L1阻断具有叠加活性,但免疫治疗成功时靶向抗原的性质仍待明确。

要点

  • RCC基线CD8 T细胞浸润与更差预后相关。
  • RCC对PD-1/PD-L1阻断有应答,尽管肿瘤突变负荷较低。
  • 抗血管生成联合PD-1/PD-L1阻断具有叠加活性。

核心结论

  • RCC免疫微环境独特,免疫治疗成功时靶向抗原的性质仍是重要未解问题。
  • 未来方案可能为联合治疗,并基于对RCC TME更广泛的理解。

主要发现

  • RCC中基线CD8 T细胞浸润与更差预后相关。
  • RCC对PD-1/PD-L1阻断有应答,尽管肿瘤突变负荷相对较低。
  • 联合免疫检查点阻断显示疗效,抗血管生成药物联合PD-1/PD-L1阻断具有叠加活性。

临床怎么用

  • 可考虑免疫检查点联合治疗及抗血管生成联合PD-1/PD-L1阻断策略。
  • 正在开展的临床研究探索RCC TME中多种抑制机制,包括腺苷和色氨酸介导的代谢通路及细胞因子疗法。

局限性

  • 免疫治疗成功时被免疫系统靶向的抗原性质尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although kidney cancer (renal cell carcinoma [RCC]) is susceptible to immunotherapy, the immunologic aspects of the tumor microenvironment (TME) in RCC are relatively unique among tumor types. In RCC, baseline CD8 T-cell infiltration is associated with a worse prognosis. In addition, kidney cancer responds to programmed death-1/programmed death-ligand 1 blockade, despite a relatively low tumor mutation burden. Recent clinical data highlight the efficacy of combined immune checkpoint blockade and demonstrate that combining antiangiogenic agents with programmed death-1/programmed death-ligand 1 blockade has additive activity. Yet an important unanswered question in RCC is the nature of the antigens that are targeted by the immune system when immunotherapy is successful. Ongoing clinical studies are interrogating the multiple suppressive mechanisms in the RCC TME, including metabolic pathways such as those mediated by adenosine and tryptophan as well as cytokine-based therapies. Future regimens are likely to be combinatorial and may eventually be based on a broader understanding of the RCC TME and how it is modulated by both conventional and immune-based therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Drake CG, Stein MN. The Immunobiology of Kidney Cancer. J Clin Oncol. 2018. PMID: 30372396. doi:10.1200/JCO.2018.79.2648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。